LOGIN  |  REGISTER
Viking Therapeutics

Veeva Systems to Present at Upcoming Investor Conference

January 16, 2024 | Last Trade: US$281.35 2.85 -1.00

PLEASANTON, Calif., Jan. 16, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced participation in the following virtual investor conference:

  • 26th Annual Needham Growth Conference. Brent Bowman, CFO, and Paul Shawah, EVP Commercial Strategy, are presenting on Friday, January 19, 2024, at 10:15 a.m. Eastern Time.

The presentation will be webcast. Links to the live and archived webcast will be available on Veeva's investor relations website at https://ir.veeva.com.

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor Veeva's investor relations website in addition to following its press releases, SEC filings, and public conference calls and webcasts.

Investor Relations Contact: 
Gunnar Hansen
Veeva Systems Inc. 
267-460-5839
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media Contact:
Maria Scurry
Veeva Systems Inc.
781-366-7617
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Recursion

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page